End-to-End Workflow for HIV Variant Calling | Illumina Video

14 August 2014

While HIV drug resistance testing is an integral aspect of part of HIV clinical care, a method for detecting minority populations of resistant virus has become an important aspect of research. View this webinar to learn how you can leverage next-generation sequencing solutions to detect minority populations of resistant virus and streamline your workflow

Share this article on    
    
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see emea.illumina.com/company/legal.html.

© 2024 Illumina, Inc. All rights reserved.